Literature DB >> 17039276

A case of recurrent episodes of Candida parapsilosis fungemia.

Dionissios Neofytos1, Michael A Pfaller, Daniel J Diekema, David Horn.   

Abstract

Candida species is the fourth most commonly isolated organism in blood stream infections in the hospital setting. Patients with candidemia frequently succumb to this infection. For those that survive an initial candidemia, an increasing number of cases of breakthrough or recurrent candidemias have been reported in the literature. We report three episodes of C. parapsilosis fungemia in a cancer patient. Molecular testing was performed and confirmed that all these episodes occurring within an eight-month period were caused by the same organism. The incidence of recurrent candidemia is likely to increase in the near future. Studies and therapeutic interventions for patients at risk for recurrent candidemias are warranted.

Entities:  

Mesh:

Year:  2006        PMID: 17039276     DOI: 10.1007/s11046-006-0060-7

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  13 in total

1.  Clinical manifestations and molecular epidemiology of late recurrent candidemia, and implications for management.

Authors:  C J Clancy; F Barchiesi; L Falconi DiFrancesco; A J Morris; D R Snydman; V L Yu; G Scalise; M H Nguyen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2000-08       Impact factor: 3.267

Review 2.  Late recurrent Candida endocarditis.

Authors:  P G Johnston; J Lee; M Domanski; F Dressler; E Tucker; M Rothenberg; R E Cunnion; P A Pizzo; T J Walsh
Journal:  Chest       Date:  1991-06       Impact factor: 9.410

3.  Strain variation and antifungal susceptibility among bloodstream isolates of Candida species from 21 different medical institutions.

Authors:  M A Pfaller; J Rhine-Chalberg; A L Barry; J H Rex
Journal:  Clin Infect Dis       Date:  1995-12       Impact factor: 9.079

Review 4.  Management of candidal thrombophlebitis of the central veins: case report and review.

Authors:  D Benoit; J Decruyenaere; K Vandewoude; C Roosens; E Hoste; J Poelaert; F Vermassen; F Colardyn
Journal:  Clin Infect Dis       Date:  1998-02       Impact factor: 9.079

5.  Electrophoretic karyotype analysis of sequential Candida parapsilosis isolates from patients with persistent or pecurrent fungemia.

Authors:  J H Shin; D H Shin; J W Song; S J Kee; S P Suh; D W Ryang
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

6.  Medical treatment of recurrent candidemia in a patient with probable Candida parapsilosis prosthetic valve endocarditis.

Authors:  M A Zahid; S A Klotz; D R Hinthorn
Journal:  Chest       Date:  1994-05       Impact factor: 9.410

7.  Correlation of SfiI macrorestriction endonuclease fingerprint analysis of Candida parapsilosis isolates with source of isolation.

Authors:  E Pontieri; L Gregori; M Gennarelli; T Ceddia; G Novelli; B Dallapiccola; F De Bernardis; G Carruba
Journal:  J Med Microbiol       Date:  1996-09       Impact factor: 2.472

8.  Analysis by pulsed-field gel electrophoresis of Candida albicans that developed resistance during antifungal therapy.

Authors:  T Mori; M Matsumura; T Oguri
Journal:  Nihon Ishinkin Gakkai Zasshi       Date:  1998

9.  Native valve endocarditis due to Candida parapsilosis: a late complication after bone marrow transplantation-related fungemia.

Authors:  J A Cancelas; J Lopez; E Cabezudo; E Navas; J Garcia Laraña; M Jimenez Mena; P Diz; J Perez de Oteyza; L Villalon; A Sanchez-Sousa
Journal:  Bone Marrow Transplant       Date:  1994-03       Impact factor: 5.483

10.  Genotypic variation and slime production among blood and catheter isolates of Candida parapsilosis.

Authors:  M L Branchini; M A Pfaller; J Rhine-Chalberg; T Frempong; H D Isenberg
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

View more
  1 in total

1.  Candida albicans exhibit two classes of cell surface binding sites for serum albumin defined by their affinity, abundance and prospective role in interkingdom signalling.

Authors:  Claire Teevan-Hanman; Paul O'Shea
Journal:  PLoS One       Date:  2021-07-19       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.